We show that theracurmin attenuates NLRP3 inflammasome activation in the heart and reduces circulating IL-1β levels, illustrating a cardio-protective effect of the compound and the potential therapeutic benefits of a theracurmin-based treatment strategy in the setting of chronic kidney disease. This evidence concerns the gene NLRP3 and chronic kidney disease.